Oasmia’s Patented XR-17 Technology Generates Novel Cancer Combination Therapy

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Uppsala, Sweden, 2013-05-28 14:00 CEST (GLOBE NEWSWIRE) -- Combination therapies are a standard treatment for a number of cancer diseases, such as breast cancer, prostate cancer and lung cancer. OAS-19 is the first oncology product candidate to apply a dual cytostatic agent encapsulation and release mechanism in one infusion. Oasmia’s unique micellar drug delivery system XR-17 allows the combination of agents with unequal solubility properties or low solubility. This concept provides Oasmia with a new platform for further pharmaceutical development of multiple active substances in one micelle. Recent preclinical studies have shown promising results, and the company plans to start clinical studies with OAS-19 in 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news